English | 繁體

Search in the results

UM

Browse/Search Results:  1-6 of 6 Help

Selected(0)Clear Items/Page:    Sort:
Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation Journal article
Cao, Dai, Chen, Die, Xia, Jiang Nan, Wang, Wen Yan, Zhu, Guo Yuan, Chen, Li Wen, Zhang, Chuantao, Tan, Bo, Li, Hui, Li, Ying Wei. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation[J]. Biomedicine and Pharmacotherapy, 2022, 155.
Authors:  Cao, Dai;  Chen, Die;  Xia, Jiang Nan;  Wang, Wen Yan;  Zhu, Guo Yuan; et al.
Favorite | TC[WOS]:10 TC[Scopus]:10  IF:6.9/6.8 | Submit date：2023/01/31
Anti-tumor Immunity  Artesunate  Egfr-tki Resistance  Non-small-cell Lung Cancer  Pd-l1  Taz  
Berberine and Momordin Ic regulate autophagy with opposite effects on the activity of anticancer agents Thesis
HAN Bing. Berberine and Momordin Ic regulate autophagy with opposite effects on the activity of anticancer agents[D]. Macau, University of Macau, 2021.
Authors:  HAN Bing
Favorite |  | Submit date：2022/07/28
Autophagy  Natural Compounds  Breast Cancer  Nsclc  Resistance  Egfr Tki  
Combination strategies using EGFR-TKi in NSCLC therapy: Learning from the gap between pre-clinical results and clinical outcomes Journal article
Yang,Zheng, Tam,Kin Yip. Combination strategies using EGFR-TKi in NSCLC therapy: Learning from the gap between pre-clinical results and clinical outcomes[J]. International Journal of Biological Sciences, 2018, 14(2), 204-216.
Authors:  Yang,Zheng;  Tam,Kin Yip
Favorite | TC[WOS]:74 TC[Scopus]:81  IF:8.2/8.3 | Submit date：2021/03/04
Chemotherapy  Combination  Egfr-tki  Immunotherapy  Nsclc  Targeted Therapy  
Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes Journal article
Yang, Zheng, Tam, Kin Yip. Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2018, 14(2), 204-216.
Authors:  Yang, Zheng;  Tam, Kin Yip
Favorite | TC[WOS]:74 TC[Scopus]:81  IF:8.2/8.3 | Submit date：2018/10/30
Combination  Egfr-tki  Nsclc  Chemotherapy  Targeted Therapy  Immunotherapy  
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies Journal article
Tang, Zheng-Hai, Lu, Jin-Jian. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies[J]. CANCER LETTERS, 2018, 420, 242-246.
Authors:  Tang, Zheng-Hai;  Lu, Jin-Jian
Favorite | TC[WOS]:100 TC[Scopus]:109  IF:9.1/8.3 | Submit date：2018/10/30
Osimertinib  Azd9291  Egfr Tki  Resistant Mechanisms  Therapeutic Strategies  
IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities Journal article
Li Y.-B., Wang Z.-Q., Yan X., Chen M.-W., Bao J.-L., Wu G.-S., Ge Z.-M., Zhou D.-M., Wang Y.-T., Li R.-T.. IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities[J]. Cancer Letters, 2013, 340(1), 88.
Authors:  Li Y.-B.;  Wang Z.-Q.;  Yan X.;  Chen M.-W.;  Bao J.-L.; et al.
Favorite | TC[WOS]:24 TC[Scopus]:27  IF:9.1/8.3 | Submit date：2018/10/31
Angiogenesis  Breast Cancer  Egfr  Irreversible Tki